113 related articles for article (PubMed ID: 24262605)
1. Profiling of defense responses in Escherichia coli treated with fosmidomycin.
Hemmerlin A; Tritsch D; Hammann P; Rohmer M; Bach TJ
Biochimie; 2014 Apr; 99():54-62. PubMed ID: 24262605
[TBL] [Abstract][Full Text] [Related]
2. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase.
Kuntz L; Tritsch D; Grosdemange-Billiard C; Hemmerlin A; Willem A; Bach TJ; Rohmer M
Biochem J; 2005 Feb; 386(Pt 1):127-35. PubMed ID: 15473867
[TBL] [Abstract][Full Text] [Related]
3. Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives.
Messiaen AS; Verbrugghen T; Declerck C; Ortmann R; Schlitzer M; Nelis H; Van Calenbergh S; Coenye T
Int J Antimicrob Agents; 2011 Sep; 38(3):261-4. PubMed ID: 21724375
[TBL] [Abstract][Full Text] [Related]
4. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.
Zhang B; Watts KM; Hodge D; Kemp LM; Hunstad DA; Hicks LM; Odom AR
Biochemistry; 2011 May; 50(17):3570-7. PubMed ID: 21438569
[TBL] [Abstract][Full Text] [Related]
5. Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.
Brown AC; Parish T
BMC Microbiol; 2008 May; 8():78. PubMed ID: 18489786
[TBL] [Abstract][Full Text] [Related]
6. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli.
Sakamoto Y; Furukawa S; Ogihara H; Yamasaki M
Biosci Biotechnol Biochem; 2003 Sep; 67(9):2030-3. PubMed ID: 14519998
[TBL] [Abstract][Full Text] [Related]
7. α,α-Difluorophosphonohydroxamic Acid Derivatives among the Best Antibacterial Fosmidomycin Analogues.
Dreneau A; Krebs FS; Munier M; Ngov C; Tritsch D; Lièvremont D; Rohmer M; Grosdemange-Billiard C
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443699
[TBL] [Abstract][Full Text] [Related]
8. The crystal structure of E.coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation.
Mac Sweeney A; Lange R; Fernandes RP; Schulz H; Dale GE; Douangamath A; Proteau PJ; Oefner C
J Mol Biol; 2005 Jan; 345(1):115-27. PubMed ID: 15567415
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the response of Escherichia coli to fosfomycin and fosmidomycin.
Kanimoto Y; Greenwood D
Eur J Clin Microbiol; 1987 Aug; 6(4):386-91. PubMed ID: 3311734
[TBL] [Abstract][Full Text] [Related]
10. Growth medium-dependent antimicrobial activity of early stage MEP pathway inhibitors.
Sanders S; Bartee D; Harrison MJ; Phillips PD; Koppisch AT; Freel Meyers CL
PLoS One; 2018; 13(5):e0197638. PubMed ID: 29771999
[TBL] [Abstract][Full Text] [Related]
11. N-acylated sulfonamide congeners of fosmidomycin lack any inhibitory activity against DXR.
Gadakh B; Pouyez J; Wouters J; Venkatesham A; Cos P; Van Aerschot A
Bioorg Med Chem Lett; 2015 Apr; 25(7):1577-9. PubMed ID: 25726328
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives].
Shtannikov AV; Sergeeva EE; Biketov SF; Ostrovskiĭ DN
Antibiot Khimioter; 2007; 52(7-8):3-9. PubMed ID: 18986018
[TBL] [Abstract][Full Text] [Related]
13. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr).
Armstrong CM; Meyers DJ; Imlay LS; Freel Meyers C; Odom AR
Antimicrob Agents Chemother; 2015 Sep; 59(9):5511-9. PubMed ID: 26124156
[TBL] [Abstract][Full Text] [Related]
14. A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
Mercklé L; de Andrés-Gómez A; Dick B; Cox RJ; Godfrey CR
Chembiochem; 2005 Oct; 6(10):1866-74. PubMed ID: 16116659
[TBL] [Abstract][Full Text] [Related]
15. A computational study of the molecular basis of antibiotic resistance in a DXR mutant.
Krebs FS; Esque J; Stote RH
J Comput Aided Mol Des; 2019 Oct; 33(10):927-940. PubMed ID: 31654265
[TBL] [Abstract][Full Text] [Related]
16. Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues.
Devreux V; Wiesner J; Jomaa H; Rozenski J; Van der Eycken J; Van Calenbergh S
J Org Chem; 2007 May; 72(10):3783-9. PubMed ID: 17428097
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.
Takahata S; Ida T; Hiraishi T; Sakakibara S; Maebashi K; Terada S; Muratani T; Matsumoto T; Nakahama C; Tomono K
Int J Antimicrob Agents; 2010 Apr; 35(4):333-7. PubMed ID: 20071153
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
Andaloussi M; Henriksson LM; Więckowska A; Lindh M; Björkelid C; Larsson AM; Suresh S; Iyer H; Srinivasa BR; Bergfors T; Unge T; Mowbray SL; Larhed M; Jones TA; Karlén A
J Med Chem; 2011 Jul; 54(14):4964-76. PubMed ID: 21678907
[TBL] [Abstract][Full Text] [Related]
19. Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
Lienau C; Gräwert T; Alves Avelar LA; Illarionov B; Held J; Knaab TC; Lungerich B; van Geelen L; Meier D; Geissler S; Cynis H; Riederer U; Buchholz M; Kalscheuer R; Bacher A; Mordmüller B; Fischer M; Kurz T
Eur J Med Chem; 2019 Nov; 181():111555. PubMed ID: 31382119
[TBL] [Abstract][Full Text] [Related]
20. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
